ArticleJournal of neurology2026

Long-term disability after initiation of platform versus high-efficacy disease-modifying therapy in relapsing-onset multiple sclerosis.

Jie Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.